These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 37814696)
1. Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma. Su R; Chen Z; Hu H; Jiang S; Chen M; Chen Q; Gellhaus PT; Ornellas AA; Campobasso D; Wei Q; Huang J; Bao Y; Xue W Transl Androl Urol; 2023 Sep; 12(9):1416-1425. PubMed ID: 37814696 [TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy. Huang J; Su R; Chen Z; Jiang S; Chen M; Yuan Y; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Li C; Wang Z; Bao Y; Cai M; Guo J; Wei Q; Xue W Oncoimmunology; 2022; 11(1):2124691. PubMed ID: 36148322 [TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer. Tsung I; Green E; Palmbos P; Sloan Z; Reichert ZR; Vaishampayan U; Smith DC; Caram MEV; Yentz S; Daignault-Newton S; Hurley L; Nguyen CB; Kraft S; Alva A J Urol; 2023 Jan; 209(1):121-130. PubMed ID: 36317715 [TBL] [Abstract][Full Text] [Related]
4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients. Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098 [TBL] [Abstract][Full Text] [Related]
5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. Sridhar SS; Blais N; Tran B; Reaume MN; North SA; Stockler MR; Chi KN; Fleshner NE; Liu G; Robinson JW; Mukherjee SD; Rahim Y; Winquist E; Booth CM; Nguyen NT; Beardsley EK; Alimohamed NS; McDonald GT; Ding K; Parulekar WR JAMA Oncol; 2020 Nov; 6(11):1751-1758. PubMed ID: 32940628 [TBL] [Abstract][Full Text] [Related]
7. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]. Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798 [No Abstract] [Full Text] [Related]
8. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial. Sonoda T; Umeda Y; Demura Y; Tada T; Nakashima K; Anzai M; Yamaguchi M; Shimada A; Ohi M; Honjo C; Waseda Y; Akai M; Ishizuka T Cancer Med; 2023 Jun; 12(12):13041-13053. PubMed ID: 37081729 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. Zhang F; Huang D; Zhao L; Li T; Zhang S; Zhang G; Yuan F; Zhang J; Zhang Y; Zhao Z; Cui L; Zhao J; Wang G; Cai S; Bai Y; Wang J; Hu Y Ther Adv Med Oncol; 2020; 12():1758835920936882. PubMed ID: 32670420 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study. Su R; Chen Z; Hong D; Jiang S; Yuan Y; Cai X; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Huang J; Wang Z; Bao Y; Cai M; Guo J; Chen M; Wei Q; Huang J; Xue W Cancer Med; 2023 May; 12(9):10587-10596. PubMed ID: 36952461 [TBL] [Abstract][Full Text] [Related]
12. Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer. Adomi S; Fujita K; Kita H; Kuwahara K; Akashi Y; Nishimoto M; Matsumura N; Sugimoto K; Minami T; Nozawa M; Yoshimura K; Tahara H; Hirayama A; Nishioka T; Esa A; Uemura H Cancer Diagn Progn; 2023; 3(4):484-490. PubMed ID: 37405216 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of cytoreductive surgery for metastatic upper tract urothelial carcinoma: a Surveillance, Epidemiology and End Results (SEER) study of 508 patients. Hu H; Lai S; Ni R; Wang M; Lai C; Ji J; Xu T; Hu H Transl Androl Urol; 2024 Jun; 13(6):983-993. PubMed ID: 38983475 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer. Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772 [TBL] [Abstract][Full Text] [Related]
15. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer. Li Y; Zhao Y; Gong C; Xie Y; Hu X; Zhang J; Wang L; Zhang S; Cao J; Tao Z; Wang B Sci Rep; 2019 Mar; 9(1):3563. PubMed ID: 30837503 [TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study. Chen Z; He Y; Ding C; Chen J; Gu Y; Xiao M; Li Q Onco Targets Ther; 2023; 16():923-935. PubMed ID: 37965584 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518 [TBL] [Abstract][Full Text] [Related]
18. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. Xu B; Cheng H; Li K; Lv Y; Zeng X; Liu T; Yu W; Guo W J Cancer Res Clin Oncol; 2022 Nov; 148(11):3029-3038. PubMed ID: 34973080 [TBL] [Abstract][Full Text] [Related]
19. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study. Yin C; Zou GR; He Y; Li J; Yan HW; Su Z; Cao XL; Li XB J Thorac Dis; 2023 Apr; 15(4):1838-1847. PubMed ID: 37197501 [TBL] [Abstract][Full Text] [Related]
20. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer. Mu F; Fan B; Li H; Qin W; Wang C; Zou B; Wang L Future Oncol; 2023 Jun; 19(19):1367-1378. PubMed ID: 37114967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]